Funding for this research was provided by:
Fresenius Kabi Deutschland, GmbH
Received: 9 December 2021
Accepted: 9 May 2022
First Online: 2 June 2022
: The main protocol of this study was approved by the by the Ethics Commission of the medical faculty from the Christian Albrecht University, in Kiel, Germany, under the number A102/17 (30/08/2017), and by the local respective independent ethic committees. Written, informed consent to participate must and will be obtained from all participants prior to enrolment, either at screening or at a deferred time point, wherever applicable and according to local regulations. Patients’ insurance covering the study period and including post-trial care considerations is ensured, as required by applicable legislation.
: Wolfgang Buhre is member of the Steering Committee of the Prodigy Study (sponsored by Medtronic), POSE Study (supported by ESAIC), Designation Study (Supported with a grant from ZonMw), and PI of the AMAZONE study (supported with grants from the Dutch Cancer Society and ESAIC). Ute Brauer (Chief Medical Officer), Tamara Dehnhardt (Director Clinical Operations) and Sonja Schmier (Senior Scientific Manager) are employees of B. Braun Melsungen AG. Martin Westphal (Chief Medical Officer), Dirk Dormann (Vice-President Medical Affairs) and Martin Hernández-González (Director Medical Writing) are employees of Fresenius Kabi Deutschland GmbH.